Association of promoter methylation and 32-bp deletion of the PTEN gene with susceptibility to metabolic syndrome

Hashemi,Mohammad; Rezaei,Hamzeh; Eskandari-Nasab,Ebrahim; Kaykhaei,Mahmoud-Ali; Taheri,Mohsen

doi:10.3892/mmr.2012.1174

Association of promoter methylation and 32-bp deletion of the PTEN gene with susceptibility to metabolic syndrome

Authors:
- Mohammad Hashemi
- Hamzeh Rezaei
- Ebrahim Eskandari-Nasab
- Mahmoud-Ali Kaykhaei
- Mohsen Taheri
View Affiliations

Affiliations: Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran, Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran, Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran, Genetics of Non Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
Published online on: November 8, 2012 https://doi.org/10.3892/mmr.2012.1174
Pages: 342-346

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolic syndrome (MeS), a cluster of several metabolic disorders, is increasingly being recognized as a risk factor for type II diabetes (T2D) and cardiovascular disease. Genetic and epigenetic alteration of the phosphatase and tensin homolog deleted on chromosome ten (PTEN) has been associated with components of MeS. The aim of the present study was to investigate the possible association of a 32-bp deletion polymorphism and promoter methylation of the PTEN gene with MeS. DNA was extracted from the peripheral blood of 151 subjects with and 149 subjects without MeS. The 32-bp deletion variant of PTEN was detected by polymerase chain reaction (PCR) and PTEN promoter methylation was defined by a nested methylation‑specific PCR (MSP) method. No significant differences were found in the allelic and genotypic frequencies of the 32-bp deletion variant of PTEN between the groups [odds ratio (OR), 0.77; 95% confidence interval (CI), 0.41-1.45; P=0.431]. However, patients with MeS were identified to have lower levels of PTEN promoter hypermethylation than subjects without MeS. Promoter methylation may be a protective factor against susceptibility to MeS (OR, 0.52; 95% CI, 0.29-0.92; P=0.029). Our findings suggest that PTEN promoter methylation may be a mechanism for PTEN downregulation or silencing in MeS, which remains to be fully clarified.

View Figures

View References

1	Church T: Exercise in obesity, metabolic syndrome, and diabetes. Prog Cardiovasc Dis. 53:412–418. 2011. View Article : Google Scholar : PubMed/NCBI
2	Abete I, Goyenechea E, Zulet MA and Martinez JA: Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis. 21(Suppl 2): B1–B15. 2011. View Article : Google Scholar : PubMed/NCBI
3	Azimi-Nezhad M, Herbeth B, Siest G, et al: High prevalence of metabolic syndrome in Iran in comparison with France: what are the components that explain this? Metab Syndr Relat Disord. 10:181–188. 2012. View Article : Google Scholar : PubMed/NCBI
4	Waite KA and Eng C: Protean PTEN: form and function. Am J Hum Genet. 70:829–844. 2002.PubMed/NCBI
5	Weng L, Brown J and Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet. 10:237–242. 2001. View Article : Google Scholar
6	Fernández S, García-García M and Torres-Alemán I: Modulation by insulin-like growth factor I of the phosphatase PTEN in astrocytes. Biochim Biophys Acta. 1783:803–812. 2008.PubMed/NCBI
7	Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998.
8	Leslie NR and Downes CP: PTEN: The down side of PI 3-kinase signalling. Cell Signal. 14:285–295. 2002. View Article : Google Scholar
9	Wijesekara N, Konrad D, Eweida M, et al: Muscle-specific PTEN deletion protects against insulin resistance and diabetes. Mol Cell Biol. 25:1135–1145. 2005.
10	Clément S, Krause U, Desmedt F, et al: The lipid phosphatase SHIP2 controls insulin sensitivity. Nature. 409:92–97. 2001.
11	Qu Y, Sun L, Yang Z and Han R: Variation in the PTEN-induced putative kinase 1 gene associated with the increase risk of type 2 diabetes in northern Chinese. J Genet. 90:125–128. 2011.
12	Tsugawa K, Jones MK, Akahoshi T, et al: Abnormal PTEN expression in portal hypertensive gastric mucosa: a key to impaired PI 3-kinase/Akt activation and delayed injury healing? FASEB J. 17:2316–2318. 2003.PubMed/NCBI
13	Hers I, Vincent EE and Tavaré JM: Akt signalling in health and disease. Cell Signal. 23:1515–1527. 2011. View Article : Google Scholar : PubMed/NCBI
14	Mocanu MM and Yellon DM: PTEN, the Achilles’ heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol. 150:833–838. 2007. View Article : Google Scholar
15	Butler M, McKay RA, Popoff IJ, et al: Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes. 51:1028–1034. 2002.
16	Besson A, Robbins SM and Yong VW: PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem. 263:605–611. 1999. View Article : Google Scholar
17	Keniry M and Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 27:5477–5485. 2008.
18	Mirmohammadsadegh A, Marini A, Nambiar S, et al: Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66:6546–6552. 2006. View Article : Google Scholar : PubMed/NCBI
19	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2486–2497. 2001. View Article : Google Scholar
20	Kaykhaei MA, Hashemi M, Narouie B, et al: Prevalence of metabolic syndrome in adult population from Zahedan, southeast Iran. Iran J Public Health. 41:70–76. 2012.PubMed/NCBI
21	Hashemi M, Kordi-Tamandani DM, Sharifi N, et al: Serum paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, southeast Iran. Eur J Endocrinol. 164:219–222. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA and Torkamanzehi A: Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep. 39:937–943. 2012. View Article : Google Scholar : PubMed/NCBI
23	Hashemi M, Moazeni-Roodi AK, Fazaeli A, et al: Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res. 9:333–339. 2010. View Article : Google Scholar : PubMed/NCBI
24	Tiwari SK, Manoj G, Prasanth K, et al: Simplified and versatile method for bisulfite-based DNA methylation analysis of small amounts of DNA. J Clin Lab Anal. 23:172–174. 2009. View Article : Google Scholar : PubMed/NCBI
25	Goel A, Arnold CN, Niedzwiecki D, et al: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 64:3014–3021. 2004.
26	Mottillo S, Filion KB, Genest J, et al: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 56:1113–1132. 2010. View Article : Google Scholar : PubMed/NCBI
27	Cameron AJ, Shaw JE and Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 33:351–375. 2004. View Article : Google Scholar : PubMed/NCBI
28	Peyrou M, Bourgoin L and Foti M: PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. Dig Dis. 28:236–246. 2010. View Article : Google Scholar
29	Vinciguerra M and Foti M: PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol. 7:192–199. 2008.
30	Ding J, Gao Y, Liu R, Xu F and Liu H: Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 30:229–234. 2011.
31	Zhou XP, Hampel H, Roggenbuck J, Saba N, Prior TW and Eng C: A 39-bp deletion polymorphism in PTEN in African American individuals: implications for molecular diagnostic testing. J Mol Diagn. 4:114–117. 2002. View Article : Google Scholar : PubMed/NCBI
32	Sadeq V, Isar N and Manoochehr T: Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med Oncol. 28:420–423. 2011. View Article : Google Scholar : PubMed/NCBI
33	Phuong NT, Kim SK, Lim SC, et al: Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 130:73–83. 2011.
34	Rizvi MM, Alam MS, Ali A, Mehdi SJ, Batra S and Mandal AK: Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol. 137:1255–1262. 2011. View Article : Google Scholar : PubMed/NCBI
35	Hou P, Ji M and Xing M: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 113:2440–2447. 2008.PubMed/NCBI
36	Rutledge AC and Adeli K: Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev. 65:S13–S23. 2007. View Article : Google Scholar : PubMed/NCBI
37	Ravi Y, Selvendiran K, Meduru S, et al: Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension. Cell Biochem Biophys. Dec 29–2011.(Epub ahead of print).